Generation Bio Co. (NASDAQ:GBIO) Receives Consensus Recommendation of “Hold” from Brokerages

Generation Bio Co. (NASDAQ:GBIO) has earned a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $8.00.

A number of research firms recently commented on GBIO. Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research report on Thursday, March 7th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Generation Bio in a report on Wednesday, April 10th.

Generation Bio Trading Up 0.7 %

Shares of NASDAQ:GBIO opened at $3.01 on Friday. The company has a market capitalization of $200.10 million, a PE ratio of -1.54 and a beta of 2.79. Generation Bio has a 12-month low of $0.86 and a 12-month high of $6.98. The business’s fifty day simple moving average is $3.13 and its 200-day simple moving average is $2.21.

Generation Bio (NASDAQ:GBIO) last announced its earnings results on Wednesday, March 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.12). The business had revenue of $2.88 million for the quarter, compared to analyst estimates of $3.05 million. Research analysts predict that Generation Bio will post -1.34 EPS for the current year.

Institutional Trading of Generation Bio

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Generation Bio during the third quarter worth $51,000. TD Asset Management Inc raised its stake in Generation Bio by 72.1% in the 3rd quarter. TD Asset Management Inc now owns 406,598 shares of the company’s stock worth $1,541,000 after acquiring an additional 170,343 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new position in Generation Bio in the 4th quarter worth $50,000. Los Angeles Capital Management LLC lifted its position in Generation Bio by 315.6% during the 4th quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company’s stock worth $455,000 after acquiring an additional 209,462 shares during the period. Finally, Panagora Asset Management Inc. purchased a new stake in Generation Bio during the 4th quarter valued at about $49,000. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.